Article Text

Download PDFPDF
EP833 The prognostic impact of sphingosine-kinase 1 expression (SphK1) on ovarian cancer
  1. Z Drosos1,
  2. H Gevensleben2,
  3. S Kommoss3,
  4. T Karn4,
  5. U Holtrich4,
  6. M Graeser-Mayer5,
  7. M Anglesio6,
  8. A El-Balat4,
  9. A Rody1 and
  10. L Hanker1
  1. 1Gynecology and Obstetrics, University Lübeck, Lübeck
  2. 2Institute of Pathology, University Hospital Bonn, Bonn
  3. 3Department of Woman’s Health, Tuebingen University Hospital, Tuebingen
  4. 4Department of Obstetrics and Gynecology, Goethe University Frankfurt, Frankfurt
  5. 5Department of Gynecology, Bethesda Hospital, Moenchengladbach, Germany
  6. 6Department of Molecular Oncology, BCCA Cancer Research Centre, Vancouver, BC, Canada


Introduction/Background Sphingosine-Kinase 1 (SphK1), encoded by the SPHK1 gene, is a key enzyme of sphingolipid metabolism and overexpressed in a variety of cancer types. In the present study, we investigated the expression of SphK1 and its prognostic impact on ovarian cancers.

Methodology We used two large retrospective tissue micro array (TMA) cohorts (in total n=763) for performing immunohistochemical analysis of SphK1. The results were correlated with clinico-pathological characteristics and survival.

Results We found that SphK1 expression differed between histological ovarian cancer histotypes with most frequent low expression in clear cell carcinoma (p<0.001). In addition, low SphK1 expression was shown to significantly correlate with optimal tumour resection (p<0.001). Kaplan-Meier analysis further revealed that low SphK1 levels were associated with improved progression-free survival (PFS; 65,23 months [95% confidence interval (CI): 49,95–80,50] vs. 51,42 months [95% CI: 27,02–75,82], p=0,052) and overall-survival (OS; 100,01 months [95% CI: 83,64–116,38] vs. 75,35 months [95% CI: 59,85–90,85], p=0,049). Subsequently, the prognostic value of SphK1 expression together with clinical factors (i.e. FIGO stage, age, and residual tumour burden after surgery) was substantiated in univariate Cox regression analysis (PFS: hazard ratio (HR)=0,83 [95% CI: 0,69–1,00], p=0,052; OS: HR=0,82 [95% CI: 0,68–1,00], p=0,05).

Conclusion Our results suggest that SphK1 expression might be a prognostic factor in ovarian cancer. Low SphK1 expression seems to be associated with prolonged survival, optimal tumour debulking and clear cell subtype. To corroborate these findings, however, our results need to be validated in an independent patient cohort.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.